Collaboration

microRNA
#Collaboration #Lipid based nanoparticle (LNP) #Oncology #Partnership #Quantoom Biosciences #RNA

Quantoom and MSK unite on personalised cancer therapies

Memorial Sloan Kettering Cancer Center (MSK) and Quantoom Biosciences have executed a non-exclusive research license and supply agreement to support the development of personalised cancer therapies using Quantoom’s lipid nanoparticle (LNP) formulation technology, Ncapsulate QCX-002.  Under the agreement, MSK will use Ncapsulate QCX-002, an LNP delivery chemistry… Read More

#Cancer Research #News

Radioactive containers
#Collaboration #Crown Bioscience #Medicines Discovery Catapult #Radiopharmaceuticals

MDC and Crown Bioscience collaborate on radiopharmaceutical innovation 

Medicines Discovery Catapult (MDC) and Crown Bioscience have announced a collaboration to deliver an integrated translational biology platform for companies developing radiopharmaceuticals.   The global collaboration between MDC and Crown Bioscience will support companies across the radiopharmaceutical pipeline, whether they are advancing radiotherapeutics, exploring new isotopes, or optimising targeting agents.  The… Read More

#Business & Investment #News

RNA
#Cardiometabolic diseases #Collaboration #Novo Nordisk #Obesity #Replicate Bioscience #srRNA

Novo and Replicate partner on srRNA therapies for obesity

Novo Nordisk and Replicate Bioscience have announced a multi-year research collaboration that will combine Novo’s drug development expertise with Replicate’s srRNA platform to develop new therapeutic candidates for cardiometabolic diseases.  Under the terms of the agreement, Novo Nordisk will receive a defined exclusive, worldwide license to use Replicate’s srRNA platform… Read More

#Business & Investment #News

#Collaboration #Drug discovery #Mergers and acquisitions #Partnership

New DDW Highlights podcast: 26 August 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The news this week has emphasised the importance of shared knowledge and expertise to the… Read More

#News

#Collaboration #Drug discovery #Mergers and acquisitions #Partnership

This week in drug discovery (18-22 August) 

News round-up for 18-22 August by DDW Senior Digital Content Editor Diana Turner. The news this week has emphasised the importance of shared knowledge and expertise to the development of new drugs, whether that is through research collaboration agreements or mergers and acquisitions, with a number of new… Read More

#News

#Biomanufacturing #Collaboration #Genetics / genomics #Synthetic biology #Synthetic DNA

Synthetic biology collaboration to develop plant genomics

A collaborative project led by the Max-Planck Institute of Molecular Plant Physiology (MPI-MP), Germany, aims to develop synthetic chloroplast genomes.  Enzymatic DNA synthesis company Camena Bioscience and whole genome writing specialists Constructive Bio are the latest companies to join the project.  Until now, constructing synthetic… Read More

#News

Neuroscience
#Collaboration #JAK inhibitor #Neuroinflammation #Parkinson's #Receptor.AI #Sareum Holdings

Sareum and ReceptorAI collaborate on TYK2/JAK1 inhibitors

Sareum Holdings and Receptor.AI have entered into a strategic collaboration focused on accelerating the discovery and optimisation of blood-brain barrier (BBB)-permeable, isoform-selective TYK2/JAK1 inhibitors.  The goal of the agreement is to generate high-quality candidates suitable for preclinical development in neuroinflammatory indications, such as multiple sclerosis and Parkinson’s disease.   Sareum’s previously… Read More

#Business & Investment #News

#Artificial intelligence (AI) #Collaboration #Drug discovery #Peptides

AI-powered platform could accelerate peptide drug discovery

CRDMO BioDuro and Atombeat have announced a strategic collaboration on an AI powered platform for accelerated peptide drug discovery.  The collaboration brings together Atombeat’s in silico modeling, AI-accelerated and data-driven design platform with BioDuro’s discovery chemistry, biology and DMPK.  The combined platform aims… Read More

#News

Proteomics
#Alzheimer's #Collaboration #Nautilus Biotechnology #Neuroscience #Partnership #Proteomics

Nautilus forms partnership to better understand Alzheimer’s

Proteome analysis company Nautilus Biotechnology has announced a partnership with the Allen Institute focused on improving our understanding of neurodegenerative conditions.  The organisations will investigate the connection between the tau protein and its occurrence in neurodegenerative conditions such as Alzheimer’s disease.  Recent studies suggested that the order, timing and extent… Read More

#Business & Investment #News

Eye
#Boehringer Ingelheim #Collaboration #Ophthalmology #Re-Vana Therapeutics

Boehringer and Re-Vana partner on long-acting ophthalmic therapies

Boehringer Ingelheim and Re-Vana Therapeutics have announced a strategic collaboration and license agreement to develop first-in-class extended-release therapies for eye diseases.  Treating ophthalmic diseases often requires frequent injections directly into the eye, which can be very burdensome for patients.   Re-Vana’s drug delivery technology is designed to release treatments slowly over… Read More

#Business & Investment #News

Automated liquid handling
#Automation / robotics #Cellular assays #Collaboration #Drug discovery #Semarion #SPT Labtech

SPT Labtech and Semarion partner on automated cell-based discovery

SPT Labtech and Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory, have announced a strategic collaboration.   The partnership will integrate SPT Labtech’s firefly liquid handling platform with Semarion’s SemaCyte microcarrier technology to develop an automated workflow to simplify and accelerate key stages of adherent cell assay development. … Read More

#Business & Investment #News

#Biomanufacturing #Biopharma #Collaboration #UK

UK business and academia partner on innovative biopharma research

Twenty-three new Prosperity Partnerships will tackle key industry challenges in areas from drug manufacturing and artificial intelligence to cybersecurity. The UKRI Engineering and Physical Sciences Research Council (EPSRC) is funding the partnerships with a £41 ($55.7) million investment, matched with a further £56 ($76) million from businesses and academia.  Each… Read More

#Business & Investment #News

#Cell and gene therapy #Circio Holding #circular RNAs #Collaboration #NeoRegen Biotech #RNA

NeoRegen and Circio progress circular RNA research collaboration

Circio Holding and NeoRegen Biotech have signed a second Material Transfer Agreement (MTA) to advance their ongoing collaboration for the delivery of circular RNA (circRNA) expression-based therapeutics.   The collaboration now is progressing to the in vivo preclinical stage following successful proof-of-concept (POC) results from in vitro studies.  The collaboration… Read More

#Business & Investment #News

Patient using blood pressure monitor
#Cardiovascular disease #Collaboration #Novartis #ProFound Therapeutics

Novartis and ProFound agree cardiovascular collaboration

Novartis and ProFound Therapeutics have announced a four-year collaboration to discover and develop novel therapeutics for cardiovascular disease.  The collaboration will join ProFound’s capabilities in the identification of novel proteins from the expanded proteome as drugs and drug targets with Novartis’ cardiovascular drug development expertise.  ProFound’s ProFoundry Platform combines multi-layered… Read More

#Business & Investment #News

Neurons
#Alzheimer's #Collaboration #Enhanced Genomics #Genetics / genomics #Multi-omics #Neuroscience #University of Cambridge

Genomics partnership discovers novel targets for Alzheimer’s

Biotechnology company Enhanced Genomics has announced a strategic partnership with The ALBORADA Drug Discovery Institute at the University of Cambridge.   Funded by Alzheimer’s Research UK, The ALBORADA Drug Discovery Institute is developing the next generation of treatments for the diseases that cause dementia.   The partnership… Read More

#News

#Cardiometabolic diseases #Collaboration #GPCRs #Novo Nordisk #Obesity

Novo Nordisk and Deep Apple announce collaboration

Novo Nordisk and Deep Apple Therapeutics have announced a research collaboration and exclusive worldwide license agreement to discover and develop oral small molecule therapeutics.  The new drugs will be directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity.  Under the terms of the agreement, Deep Apple will… Read More

#Business & Investment #News